Mark your calendars for "Collaborating to Advance Health Equity for Diabetes and Chronic Kidney Disease," a conference sponsored by the University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI).

Register to Attend View the Agenda About M-CERSI

Scheduled for Wednesday, Feb. 10, 2021, "Collaborating to Advance Health Equity for Diabetes and Chronic Kidney Disease" will bring together researchers, patients, policymakers, and clinicians from across academia, government, and industry.

Important Event Information
Date: Wednesday, Feb. 10, 2021
Time: 10 a.m. - 3:05 p.m. (ET)
Location: Online Event
Registration: Online Registration Available Here

About the Event:

"Collaborating to Advance Health Equity for Diabetes and Chronic Kidney Disease" is a one-day workshop that will be open to public. This event aims to advance attendees' understanding of the following:

  1. Leveraging patient experience data and community/system approaches to inform care, drug development and overall research agenda to improve patient outcomes and reduce health inequities for diverse communities with diabetes and chronic kidney disease (CKD).
  2. Explore barriers to diversity in clinical trials for CKD and diabetes and strategies to improve diversity in clinical trials.
  3. Utilization of real-world data to inform strategies and decision making on the management of diabetes and CKD.

Regulatory Impact:

This workshop supports the Office of Minority Health and Health Equity's (OMHHE) mission; the 21st Century Cures Act to understand patient perspectives; and the 2012 Food and Drug Administration Safety and Innovation Act (FDASIA Section 907), an effort to advance inclusion of racial and ethnic minority populations in clinical trials.

For More Information:

More information about this workshop, including registration and an agenda, is available on this website.

If you have any additional questions about this workshop, please contact cersi@umd.edu.

Acknowledgement:

This workshop is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award U01FD005946 totaling $5,000 with 100 percent funded by FDA/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by FDA/HHS, or the U.S. Government.